Wednesday, December 4, 2024

NASA-Led Team Links Comet Water to Earth’s Oceans - UNIVERSE/EARTH

Scientists find that cometary dust affects interpretation of spacecraft measurements, reopening the case for comets like 67P as potential sources of water for early Earth. 

Researchers have found that water on Comet 67P/Churyumov–Gerasimenko has a similar molecular signature to the water in Earth’s oceans. Contradicting some recent results, this finding reopens the case that Jupiter-family comets like 67P could have helped deliver water to Earth.  

Water was essential for life to form and flourish on Earth and it remains central for Earth life today. While some water likely existed in the gas and dust from which our planet materialized around 4.6 billion years ago, much of the water would have vaporized because Earth formed close to the Sun’s intense heat. How Earth ultimately became rich in liquid water has remained a source of debate for scientists.

Research has shown that some of Earth’s water originated through vapor vented from volcanoes; that vapor condensed and rained down on the oceans. But scientists have found evidence that a substantial portion of our oceans came from the ice and minerals on asteroids, and possibly comets, that crashed into Earth. A wave of comet and asteroid collisions with the solar system’s inner planets 4 billion years ago would have made this possible.  

This image, taken by ESA’s Rosetta navigation camera, was taken from a about 53 miles from the center of Comet 67P/Churyumov-Gerasimenko on March 14, 2015. The image resolution is 24 feet per pixel and is cropped and processed to bring out the details of the comet's activity.

ESA/Rosetta/NAVCAM

While the case connecting asteroid water to Earth’s is strong, the role of comets has puzzled scientists. Several measurements of Jupiter-family comets — which contain primitive material from the early solar system and are thought to have formed beyond the orbit of Saturn — showed a strong link between their water and Earth’s. This link was based on a key molecular signature scientists use to trace the origin of water across the solar system.

This signature is the ratio of deuterium (D) to regular hydrogen (H) in the water of any object, and it gives scientists clues about where that object formed. Deuterium is a rare, heavier type — or isotope — of hydrogen. When compared to Earth’s water, this hydrogen ratio in comets and asteroids can reveal whether there’s a connection.  

Because water with deuterium is more likely to form in cold environments, there’s a higher concentration of the isotope on objects that formed far from the Sun, such as comets, than in objects that formed closer to the Sun, like asteroids. 

Measurements within the last couple of decades of deuterium in the water vapor of several other Jupiter-family comets showed similar levels to Earth’s water. 

“It was really starting to look like these comets played a major role in delivering water to Earth,” said Kathleen Mandt, planetary scientist at NASA’s Goddard Space Flight Center in Greenbelt, Maryland. Mandt led the research, published in Science Advances on Nov. 13, that revises the abundance of deuterium in 67P. 

About Kathleen Mandt

But in 2014, ESA’s (European Space Agency) Rosetta mission to 67P challenged the idea that Jupiter-family comets helped fill Earth’s water reservoir. Scientists who analyzed Rosetta’s water measurements found the highest concentration of deuterium of any comet, and about three times more deuterium than there is in Earth’s oceans, which have about 1 deuterium atom for every 6,420 hydrogen atoms.  

“It was a big surprise and it made us rethink everything,” Mandt said.  

Mandt’s team decided to use an advanced statistical-computation technique to automate the laborious process of isolating deuterium-rich  water in more than 16,000 Rosetta measurements. Rosetta made these measurements in the “coma” of gas and dust surrounding 67P. Mandt’s team, which included Rosetta scientists, was the first to analyze all of the European mission’s water measurements spanning the entire mission. 

The researchers wanted to understand what physical processes caused the variability in the hydrogen isotope ratios measured at comets. Lab studies and comet observations showed that cometary dust could affect the readings of the hydrogen ratio that scientists detect in comet vapor, which could change our understanding of where comet water comes from and how it compares to Earth’s water.  

What are comets made of? It's one of the questions ESA's Rosetta mission to comet 67P/Churyumov-Gerasimenko wanted to answer.

“So I was just curious if we could find evidence for that happening at 67P,” Mandt said. “And this is just one of those very rare cases where you propose a hypothesis and actually find it happening.” 

Indeed, Mandt’s team found a clear connection between deuterium measurements in the coma of 67P and the amount of dust around the Rosetta spacecraft, showing that the measurements taken near the spacecraft in some parts of the coma may not be representative of the composition of a comet’s body.  

As a comet moves in its orbit closer to the Sun, its surface warms up, causing gas to release from the surface, including dust with bits of water ice on it. Water with deuterium sticks to dust grains more readily than regular water does, research suggests. When the ice on these dust grains is released into the coma, this effect could make the comet appear to have more deuterium than it has.  

Mandt and her team reported that by the time dust gets to the outer part of the coma, at least 75 miles from the comet body, it is dried out. With the deuterium-rich water gone, a spacecraft can accurately measure the amount of deuterium coming from the comet body.

This finding, the paper authors say, has big implications not only for understanding comets’ role in delivering Earth’s water, but also for understanding comet observations that provide insight into the formation of the early solar system.  

“This means there is a great opportunity to revisit our past observations and prepare for future ones so we can better account for the dust effects,” Mandt said. 

By Lonnie Shekhtman
NASA’s Goddard Space Flight Center, Greenbelt, Md.
 

Source: NASA-Led Team Links Comet Water to Earth’s Oceans - NASA Science 

First new treatment for asthma attacks in 50 years


Asthma attacks and COPD flare-ups (also called exacerbations) can be deadly. Every day in the UK four people with asthma and 85 people with COPD will tragically die. Both conditions are also very common, in the UK someone has an asthma attack every 10 seconds. Asthma and COPD costs the NHS £5.9B a year.


The type of symptom flare-up the injection treats are called ‘eosinophilic exacerbations’ and involve symptoms such as wheezing, coughing and chest tightness due to inflammation resulting from high amounts of eosinophils (a type of white blood cell). Eosinophilic exacerbations make up to 30% of COPD flare-ups and almost 50% of asthma attacks. They can become more frequent as the disease progresses, leading to irreversible lung damage in some cases. There are two million attacks or exacerbations of this type in the UK per year.


Treatment at the point of an exacerbation for this type of asthma has barely changed for over fifty years, with steroid drugs being the mainstay of medication. Steroids such as prednisolone can reduce inflammation in the lungs but have severe side-effects such as diabetes and osteoporosis. Furthermore, many patients ‘fail’ treatment and need repeated courses of steroids, re-hospitalisation or die within 90 days.


Results from the phase two clinical trial ABRA study, led by scientists from King’s College London and sponsored by the University of Oxford, show a drug already available can be re-purposed in emergency settings to reduce the need for further treatment and hospitalisations. The multi-centre trial was conducted at Oxford University Hospitals NHS Foundation Trust and Guy’s and St Thomas’ NHS Foundation Trust.


Benralizamab is a monoclonal antibody which targets specific white blood cells, called eosinophils, to reduce lung inflammation. It is currently used for the treatment of severe asthma. The ABRA trial has found a single dose can be more effective when injected at the point of exacerbation compared to steroid tablets.


The study investigators randomised people at high risk of an asthma or COPD attack into three groups, one receiving benralizumab injection and dummy tablets, one receiving standard of care (prednisolone 30mg daily for five days) and dummy injection and the third group receiving both benralizumab injection and standard of care. As a double-blind, double-dummy, active-comparator placebo-controlled trial, neither the people in the study, or the study investigators knew which study arm or treatment they were given.


After 28 days, respiratory symptoms of cough, wheeze, breathlessness and sputum were found to be better with benralizumab. After ninety days, there were four times fewer people in the benralizumab group that failed treatment compared to standard of care with prednisolone.

Treatment with the benralizumab injection took longer to fail, meaning fewer episodes to see a doctor or go to hospital. There was also an improvement in the quality of life for people with asthma and COPD.

She added: “Benralizumab is a safe and effective drug already used to manage severe asthma. We’ve used the drug in a different way – at the point of an exacerbation – to show that it’s more effective than steroid tablets which is the only treatment currently available. The big advance in the ABRA study is the finding that targeted therapy works in asthma and COPD attacks. Instead of giving everyone the same treatment, we found targeting the highest risk patients with very targeted treatment, with the right level of inflammation was much better than guessing what treatment they needed.”

The benralizumab injection was administered by healthcare professionals in the study but can be potentially administered in the GP practice or in the Emergency Department. Benralizumab was safe in the study and similar in safety to many past studies.

Professor Mona Bafadhel said, “We hope these pivotal studies will change how asthma and COPD exacerbations are treated for the future, ultimately improving the health for over a billion people living with asthma and COPD across the world.”

Dr Sanjay Ramakrishnan, Clinical Senior Lecturer at the University of Western Australia, who is the first author of the ABRA trial and started the work while at the University of Oxford, said: “Our study shows massive promise for asthma and COPD treatment. COPD is the third leading cause of death worldwide but treatment for the condition is stuck in the 20th century. We need to provide these patients with life-saving options before their time runs out.

“The ABRA trial was only possible with collaboration between the NHS and universities and shows how this close relationship can innovate healthcare and improve people’s lives.”

Geoffrey Pointing, 77 from Banbury, who took part in the study, said: “Honestly, when you’re having a flare up, it’s very difficult to tell anybody how you feel – you can hardly breathe. Anything that takes that away and gives you back a normal life is what you want. But on the injections, it’s fantastic. I didn’t get any side effects like I used to with the steroid tablets. I used to never sleep well the first night of taking steroids, but the first day on the study, I could sleep that first night, and I was able to carry on with my life without problems. I want to add that I’m just grateful I took part and that the everyone involved in the ABRA study are trying to give me a better life.”

Dr Samantha Walker, Director of Research and Innovation, at Asthma + Lung UK, said: “It’s great news for people with lung conditions that a potential alternative to giving steroid tablets has been found to treat asthma attacks and chronic obstructive pulmonary disease (COPD) exacerbations. But it’s appalling that this is the first new treatment for those suffering from asthma and COPD attacks in 50 years, indicating how desperately underfunded lung health research is.

“Every four minutes in the UK, someone dies from a lung condition. Thousands more live with the terror of struggling to breathe every day. With your help, we’re fighting for more life-changing, life-saving research to transform the future for everyone living with breathing problems. Together, we’ll make sure that families everywhere never face a lung condition without the best treatment and care.

Story via https://www.kcl.ac.uk/news/first-new-treatment-asthma-attacks-in-50-years 

Source: First new treatment for asthma attacks in 50 years – Scents of Science 

Why Pandas Are Impressively Bad at Existing - Real Science

 

EXTREME CLOSE CALLS 2024 (caught on dashcam) | PART 4 - Dashcam Lessons

 

Short Clip -Bruce Almighty : Deleted Scenes (Jim Carrey, Morgan Freeman, Jennifer Aniston) - Comedy - Fantasy


 

Suki Waterhouse on new album, baby with Robert Pattinson & opening for Taylor Swift | 8 Before 8 - TODAY

 

A New Galactic Adventure | SKELETON CREW | Star Wars Spin-Off Series


 

SNOW WHITE Trailer 2 (2025) Gal Gadot, Rachel Zegler



 

LAST BREATH Trailer (2025) Woody Harrelson

 

LIGHT SHOP Trailer (2024) Park Bo-young, Mystery, Thriller

 

TRAP CITY Trailer (2024) Crime, Drama Movie HD

 

THE SECOND ACT Trailer (2024) Léa Seydoux


BLOODY AXE WOUND Trailer (2025) Jeffrey Dean Morgan, Horror, Comedy Movie HD

 

Funny and Weird Clips (3450)




















 

Tuesday, December 3, 2024

What's Up: December 2024 Skywatching Tips from NASA - NASA Jet Propulsion Laboratory - UNIVERSE

 

Men at high risk of heart disease face earlier brain health decline than women

A study using UK Biobank data has found that high cardiovascular risk factors, including obesity, are linked to accelerated brain volume loss, affecting the regions in the temporal lobe that are crucial for memory and sensory processing.

The long term observational study found that men were susceptible to the decline a decade earlier (from their mid-50s) compared to similarly-affected women (from their mid-60s).  

Professor Paul Edison at Imperial College London’s Department of Brain Sciences, who led the study, said: “It was important to learn that cardiovascular disease on dementia had such a profound influence in males a decade earlier than in females, and this was not previously known. This has significant implications for how we treat cardiovascular disease in men and women to prevent dementia in future.”

While cardiovascular disease risk factors – such as type 2 diabetes, obesity and high blood pressure -were known to be linked with a greater risk of developing dementia, researchers in this study wanted to understand what the best time to intervene with treatment to stave off the associated decline would be – and whether this differed between the sexes. 

By examining over 34,000 participants of the UK Biobank, all of whom had abdominal and brain scans, the researchers were able to identify the effect of cardiovascular risk, abdominal fat, and the fat that surrounds body organs (visceral adipose tissue) on brain changes.

Analysis of the data showed that higher levels of abdominal fat and visceral adipose tissue were associated with lower brain grey matter volume in both men and women.

This negative impact begins a decade earlier in men (mid-50s) compared to women (mid-60s), persisting for two decades and irrespective of the APOE ε4 gene which is linked to a higher risk of developing Alzheimers disease.

Now, the researchers suggest that aggressively managing cardiovascular risk factors, especially before age 55, could be crucial in preventing neurodegeneration.

Professor Edison explained; “Targeting cardiovascular risk and obesity a decade earlier in males than females may be vital in preventing diseases like Alzheimer’s. It’s possible that repurposing existing drugs for obesity and cardiovascular disease are a potential way of treating this and other degenerative brain conditions.”  

Cardiovascular risk and obesity impact loss of grey matter volume earlier in males than females is published online in the Journal of Neurology Neurosurgery & Psychiatry

Story via https://www.imperial.ac.uk/news/258793/men-high-risk-heart-disease-face/ 

Source: Men at high risk of heart disease face earlier brain health decline than women – Scents of Science   

The Greatest Mathematician Who Ever Lived - Newsthink

 

Best Fails of the Week | Ridin’ Dirty 😎 - FailArmy

 

Short Film - Filthy Boy - Naughty Corner - Music



 

Jordana Brewster on the future of the Fast Saga - JoBlo Celebrity Interviews


 

EXCLUSIVE: Behind-the-Scenes Look at NOSFERATU | Official Featurette | IMDb

 

A BROOKLIN LOVE STORY Trailer (2024) Katie McCarty, Romance

 

PLAYING NICE Trailer (2024) James Norton